Search Results

John Streicher About this episode Our guest in this episode of the Dr.GPCR podcast is Dr. John Streicher from the department of pharmacology at the University of Arizona. John started grad school in 1999 and spent some time figuring out what he was interested in. Today, John and his team focus on understanding how signal transduction cascades downstream of the opioid John Streicher on the web University of Arizona Department of Pharmacology Google Scholar Pubmed LinkedIn

John Janetzko About Dr. John's scientific content. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen John's Chemistry Olympiad and GPCR Journey John shared his experience with the Chemistry Olympiad program John's Scientific Journey and Lab Collaboration John discussed his scientific journey, starting with

GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery Currently serving as a Post Doctoral research fellow at Monash University, John plays a pivotal role Clinical Research Associate at IQVIA and regulatory officer at the Food and Drug Authority (FDA) in Ghana, John Driven by a passion for advancing drug development, John is committed to leveraging his expertise to John Azietaku on the web LinkedIn Dr.

Jennifer is currently an assistant professor of physiology at the Johns Hopkins School of Medicine. Jennifer Pluznick on the web John Hopkins Pluznick Lab Pubmed Ted Talk Dr.

During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the He then joined WL/PD, where his lab demonstrated the existence of two subtypes of the adenosine A2 receptor In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab.

Raul Gainetdinov Raul R. Before SPBU, Raul R. Before joining the Department of Cell Biology in 1996 as a postdoc and becoming faculty at Duke in 2000 In 2018-2020, Raul R.

<< Back to podcast list Strategic Partner(s) Scott Struthers R. R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.

John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid

He then went on to earn a Ph.D. in Molecular Biophysics from Johns Hopkins University, followed by postdocs

progressed through the ranks at Warwick to become an Associate Professor before leaving in 2015 to join the Department of Pharmacology at Cambridge, where he is also a Fellow of St John’s College.

After that, I worked at Johns Hopkins in Baltimore as a research assistant investigating mechanisms and

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns

Randy then joined the faculty at the Emory University School of Medicine in 1999. Keck Foundation, and the John J. Abel Award from ASPET . Join me to learn more about Randy’s work, hear his insights on the GPCR field, and also hear the story

story behind pH Sense, Revvity’s innovative GPCR internalization assay, and his journey in GPCR product R& Eric Trinquet is Head of R&D for Life Sciences Reagents at Revvity, where he leads innovation in biochemical Join the Dr. . 👉 Join now Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr.

Before joining BioTek in 2008, Banks was employed by PerkinElmer for a decade. These roles included management of PerkinElmer’s BioPharma R&D program and Chair of the company’s Scientific

discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&

Yamina Berchiche on the web D r.

I have 10 years of experience in the development and management of R&D projects and teams in the field In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo

Who Should Join To join the community, you should be actively related to the GPCR field , including: Academic researchers (PI, postdoc, student) Industry scientists and R&D leaders Biotech and pharma founders

Following this, he joined an early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development team, pursued international strategic partnerships, managed IP

He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).

John Traynor and Dr.

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics

In 2017 I officially joined the PhD program in the Department of Molecular Physiology and Biophysics Since I joined the lab, I became proficient in many In-vivo techniques, I adapted my arrestin recruitment John McCorvy , Dr. Dylan Eiger , and Joshua Gross. We are very excited about this event.

Optimized CRO Collaboration: Streamline internal R&D and external CRO workflows to prevent delays and focused execution accelerates preclinical milestones and maximizes the efficiency and return on your R&

Jens Carlsson, Professor of Computational Biochemistry at Uppsala University, joins Dr. chemists and structural biologists Early-career researchers exploring drug discovery Biotech leaders and R&

Before joining Revvity, Eric worked for Cisbio Bioassays first as Director of Technological Development and then as R&D Director. Elodie DUPUIS R&D Senior project manager, team leader. She then joined Cisbio Bioassays, and later Revvity, as project leader and team manager in the Research He joined Revvity (then Cisbio) in 2016 as part of the scientific marketing effort to build brand recognition

He joined Mount Sinai through FlexMed — bypassing the MCAT — and was torn between a career in pharma About Alex Serafini Alex was born and raised in the Bay Area and received his BS/MS Neuroscience from Johns Upon matriculating to Mount Sinai's MD/PhD program, he joined Dr.